Gene-Silencing Therapy EPI-321 Shows Early Evidence of Increased Muscle Volume in Phase 1/2 FSHD Study
Interim phase 1/2 data showed increased lean muscle volume and a favorable safety profile following a single dose of EPI-321 in the first three evaluable patients with facioscapulohumeral muscular dystrophy.
Epicrispr Biotechnologies has announced interim findings from its ongoing phase 1/2 first-in-human study (NCT06907875) evaluating EPI-321, an investigational epigenetic gene-silencing therapy for facioscapulohumeral muscular dystrophy (FSHD). Early data demonstrated increases in lean muscle volume among the first 3 evaluable patients treated with a single dose of the therapy, alongside a favorable safety profile, representing what the company describes as the first reported clinical evidence of increased muscle volume following treatment in patients with FSHD.¹
The findings are notable because FSHD is characterized by progressive skeletal muscle degeneration and weakness, with affected individuals typically experiencing ongoing muscle loss over time. Although advances have been made in understanding the genetic basis of the disease, there are currently no approved disease-modifying therapies capable of slowing or reversing disease progression.²
"These results represent a major scientific breakthrough for both the FSHD community and the field of epigenetic medicine," Amber Salzman, PhD, chief executive officer of Epicrispr Biotechnologies, said in a statement.¹ "For the first time, we are seeing clinical evidence that a therapy may suppress the genetic driver of FSHD and increase muscle volume."
Early Clinical Findings
The ongoing open-label phase 1/2 trial is evaluating the safety, tolerability, biological activity, and preliminary efficacy of EPI-321 in adults with FSHD, with 9 participants treated across 2 dose cohorts as of the May 12, 2026 data cutoff. In total, 6 participants received a single intravenous infusion at the target dose of 2 × 10¹³ vg/kg, while 3 participants received a higher dose of 4 × 10¹³ vg/kg.¹
Among the first 3 participants who completed 6 months of follow-up in the target-dose cohort, investigators observed increases in lean muscle volume compared with baseline. Average gains measured approximately 370 mL, equivalent to roughly 0.8 pounds of lean muscle, with individual increases ranging from approximately 0.5 to 1.3 pounds. Some individual muscles demonstrated increases in lean muscle volume of up to 15%. Additionally, no serious adverse events have been reported to date according to the company.
Epicrispr also reported reductions in a circulating cell-free DNA biomarker intended to reflect DUX4 pathway activity. According to the company, these biomarker findings were directionally consistent with the MRI-based increases in lean muscle volume as well as previously reported favorable trends in strength and functional assessments collected at three months. However, detailed statistical analyses, comparisons between dose cohorts, and longer-term clinical outcomes have not yet been reported.
Targeting the Genetic Driver of FSHD
Unlike many investigational therapies that attempt to reduce downstream inflammation or muscle degeneration, EPI-321 is designed to directly suppress expression of DUX4, the transcription factor widely recognized as the primary genetic driver of FSHD.³
In healthy skeletal muscle, DUX4 is normally silenced after early embryonic development. In individuals with FSHD, however, epigenetic abnormalities permit inappropriate DUX4 expression in adult muscle tissue, triggering inflammatory signaling, impaired muscle regeneration, oxidative stress, and progressive muscle cell death.²
EPI-321 utilizes Epicrispr's Gene Expression Modulation System (GEMS), an epigenetic editing platform intended to durably suppress DUX4 expression without permanently altering the underlying DNA sequence. The therapy is administered as a single intravenous infusion and is designed to provide long-lasting repression of disease-causing gene activity.
Gene-silencing approaches targeting DUX4 have emerged as one of the leading disease-modifying strategies under investigation for FSHD, reflecting growing consensus that directly addressing the initiating molecular defect may provide broader therapeutic benefit than downstream symptomatic interventions alone.
Limitations and Next Steps
The current analysis represented an interim assessment of an ongoing first-in-human study. Only 3 participants had reached the 6-month evaluation included in this report, limiting conclusions regarding efficacy, durability, and generalizability.
Additional follow-up is ongoing across both dose cohorts, and Epicrispr expects to present updated data at the World Muscle Society Annual Congress in September 2026. Completion of the primary portion of the phase 1/2 study is anticipated in mid-2027.¹
If subsequent studies confirm durable DUX4 suppression alongside improvements in muscle structure and clinical function, EPI-321 could become one of the first disease-modifying therapies to directly target the underlying molecular cause of FSHD.
